Sun Pharmaceutical Industries Ltd Q2FY26: ₹14,478 Cr Sales, ₹3,125 Cr PAT, ₹200 Mn Settlement — The Pharma King Gets Its Halol Hiccups Again
1. At a Glance
If the Indian pharma world had a monarchy, Sun Pharma would be the guy wearing the golden stethoscope — ruling the chronic disease kingdom while occasionally paying fines to the FDA like traffic challans. With a market cap of ₹4,05,488 crore, this ₹1,690-per-share juggernaut just reported Q2FY26 consolidated sales of ₹14,478 crore and PAT of ₹3,125 crore, modestly up 2.6% QoQ and 8.9% YoY. But wait — there’s also the ₹200 million (₹1,670 crore) US settlement in the background. Because apparently, global pharma domination comes with “legal vitamins.”
Operating profit? A healthy ₹4,527 crore, pushing operating margins to a tasty 31%, up from 29% last quarter. Stock’s P/E stands at 35x, ROE at 16.9%, and dividend yield at 0.95% — all of which scream “we’re rich but not reckless.” Debt? Barely ₹5,215 crore, giving it a 0.07x D/E ratio — practically debt-free.
So yes, Dilip Shanghvi’s empire is still minting profits, facing FDA slap-and-heal routines, and launching new dermatology blockbusters like LEQSELVI while most rivals are still figuring out their glucose levels.
2. Introduction
Welcome to the wonderful, confusing world of Indian pharma, where every company either dreams of being Sun Pharma or dreams of being sued like it. For a firm that started in 1983 making psychiatry drugs, Sun now makes everything from antidepressants to billion-dollar settlements.
In Q2FY26, the company once again flexed its global presence — 41 manufacturing sites, 380 APIs, 26+ specialty brands, and operations across 100+ countries. The quarter wasn’t scandal-free, of course. The US FDA’s Halol facility once again made headlines with an OAI (Official Action Indicated) classification, basically FDA’s way of saying “bro, clean your kitchen.”
Meanwhile, Sun continued doing what it does best: collecting therapies like Pokémon cards — dermatology, ophthalmology, onco-dermatology, you name it. And just when analysts thought Sun had run out of steam, it announced a $355 million acquisition of Checkpoint Therapeutics, adding more firepower to its oncology arsenal.
Is Sun Pharma’s business too big to fail, or too complicated to fully understand? Maybe both. But one thing is clear — in an industry of generic players, Sun’s strategy remains very brand-conscious.
3. Business Model – WTF Do They Even Do?
Think of Sun Pharma as that overachieving cousin who doesn’t just study medicine — he also owns the hospital, pharmacy, and probably your blood test lab. The company runs five global segments, and every one of them contributes meaningfully to the ₹55,000 crore annual revenue pie.
a) India Branded Generics (32% of 9M FY25 revenue) — the home turf and cash cow. With 8.2% market share, Sun dominates in neuropsychiatry, cardiology, gastroenterology, diabetes, and pain management. Basically, if you have stress, reflux, or a heart condition, there’s a good chance your medicine box already says “Sun.”
b) US Formulations (31%) — Sun is the 12th largest generic pharma company in the US, and second in dermatology prescriptions. The US market’s 7% YoY growth shows Sun knows how to survive America’s brutal price wars — with dermatology leading the way.
c) Emerging Markets (18%) — Sun’s empire spreads from Brazil to Romania, where its 2,500+ sales reps hustle to push Revital H, Volini, and other global household names.
d) Rest of World (14%) — Western Europe, Canada, Australia, Japan — this segment’s basically “everywhere else that buys medicines.”
e) APIs & Consumer Healthcare (5%) — the hidden muscle. Sun makes 380 APIs (the chemical building blocks for drugs) and sells consumer brands like Volini, Abzorb, and Revital H across 25+ countries.
So yes, Sun Pharma doesn’t just make pills. It makes the pills that make other pills possible.
Commentary: Margins are healthier than an oat-eating yoga instructor. Operating profit at 31% OPM signals Sun’s specialty strategy is paying off. PAT jumped 36% QoQ — proof that R&D isn’t just an expense line but a money printer.
5. Valuation Discussion – Fair Value Range (Educational Only)
Disclaimer: This fair value range is for educational
